Exploratory/Developmental Research on Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (R21 - Clinical Trial Not Allowed) (RFA NS-25-025)

Exploratory/Developmental Research on Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (R21 - Clinical Trial Not Allowed) (RFA NS-25-025) is sponsored by National Institutes of Health (NIH). This NIH funding opportunity supports exploratory research to investigate mechanisms of Guillain Barre Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy.

Exploratory/Developmental Research on Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (R21 - Clinical Trial Not Allowed) | RFA NS 25 025 Exploratory/Developmental Research on Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (R21 - Clinical Trial Not Allowed) | RFA NS 25 025 National Institutes of Health Opportunity Information: Apply for RFA NS 25 025 The National Institutes of Health (NIH) is offering an R21 exploratory/developmental research grant opportunity titled "Exploratory/Developmental Research on Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (R21 - Clinical Trial Not Allowed)."

Listed under Funding Opportunity Number RFA-NS-25-025 and CFDA 93. 853, this discretionary health research grant is designed to speed up early-stage, high-impact studies that can move the field toward a clearer understanding of disease biology and, ultimately, better ways to diagnose, monitor, and treat both GBS and CIDP.

The opportunity specifically emphasizes exploratory work, meaning applicants are generally expected to propose innovative ideas, proof-of-concept studies, or development of new approaches rather than large, definitive clinical efficacy trials.

The central goal of the initiative is to accelerate research that explains how immune-mediated processes lead to nerve damage and dysfunction in GBS and CIDP, and how those processes might be intercepted, measured, or reversed. Responsive projects can focus on immunological mechanisms, such as the immune pathways and cellular players that drive inflammation, demyelination, axonal injury, and impaired nerve signaling.

Proposals can also address contributing genetic and epigenetic factors that may influence disease susceptibility, severity, recovery trajectories, relapse risk, or treatment responsiveness.

In addition, the announcement encourages development of novel animal models and cellular model systems that better capture key features of GBS or CIDP, since improved models can enable faster testing of hypotheses about disease triggers and immune-nerve interactions. A major area of interest is biomarker discovery and development.

This includes identifying diagnostic biomarkers that could improve accuracy or speed of diagnosis, as well as biomarkers that can predict prognosis, stratify patients, or track disease activity over time. The opportunity also highlights treatment-response biomarkers, which could help clinicians determine whether a therapy is working earlier than current clinical assessments allow.

Beyond biomarkers, the initiative supports research into novel treatments as well as studies that clarify the mechanisms of action of existing treatments. This could include work that explains why certain therapies help some patients but not others, what immune pathways are actually being modulated, or how treatment timing and biological context affect outcomes.

Because the FOA states "Clinical Trial Not Allowed," applicants should design studies that do not meet NIH’s definition of a clinical trial; however, mechanistic human studies, analyses of biospecimens, and observational or translational work may still be relevant as long as they are structured appropriately and remain outside the clinical trial definition.

Eligibility is broad and includes many types of domestic institutions and organizations, reflecting NIH’s intent to draw ideas from across the research ecosystem.

Eligible applicants include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; and Native American tribal organizations that are not federally recognized tribal governments.

Nonprofit organizations are eligible whether or not they have 501(c)(3) status (as long as they are not institutions of higher education in the category specified), and for-profit organizations are also eligible (other than small businesses), as are small businesses under the general eligibility umbrella listed. Public housing authorities and Indian housing authorities are included as eligible entities as well.

The announcement further calls out additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and non-U.S. (foreign) organizations, indicating that NIH is open to participation from a wide range of communities and institutional settings, including international contributors when permitted.

Key administrative details included in the source data are that the opportunity is a grant (Funding Instrument Type: Grant) in the health category, created on 2024-11-13, with an original application closing date of 2025-10-03.

The listing shows an award ceiling of $3,000,000, which represents the maximum amount shown in the opportunity record; applicants should still verify the allowed budget structure and project period expectations for an R21 mechanism in the full FOA, since R21 budgets are often constrained by mechanism-specific guidelines and institute policies.

The record does not specify the expected number of awards, which suggests that the number of funded projects may depend on the quantity and quality of applications received and the funds NIH ultimately allocates to this initiative. Overall, this funding opportunity is aimed at jump-starting creative, early-stage research that can open new paths in GBS and CIDP science.

The strongest applications are likely to be those that clearly identify a major gap in understanding or clinical need, propose a rigorous and feasible approach to generate decisive preliminary data, and show how the work could translate into improved diagnostic tools, better disease monitoring, clearer patient stratification, or more effective therapeutic strategies, all while staying within the "no clinical trial" boundary set by the FOA.

The National Institutes of Health in the health sector is offering a public funding opportunity titled " Exploratory/Developmental Research on Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (R21 - Clinical Trial Not Allowed) " and is now available to receive applicants. Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93. 853 .

This funding opportunity was created on 2024-11-13. Applicants must submit their applications by 2025-10-03. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)

Each selected applicant is eligible to receive up to $3,000,000. 00 in funding.

Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: Your browser does not support the video tag.

Browse more opportunities from the same agency: National Institutes of Health Browse more opportunities from the same category: Health Next opportunity: Social disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional) Previous opportunity: DRL Request for Statements of Interest on Programs to Support Democratic Reform and Human Rights in Burma Are you interested in learning about about how to apply for this government funding opportunity?

You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Applicants also applied for: Applicants who have applied for this opportunity (RFA NS 25 025) also looked into and applied for these: Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed) Apply for PAR 25 202 Funding Number: PAR 25 202 Agency: National Institutes of Health Funding Amount: Case Dependent Focused Technology Research and Development (R01 Clinical Trial Not Allowed) Apply for PAR 25 203 Funding Number: PAR 25 203 Agency: National Institutes of Health Funding Amount: Case Dependent Global Health Security Activity Apply for 72052025RFA00002 Funding Number: 72052025RFA00002 Agency: Guatemala USAID-Guatemala City Funding Amount: $40,000,000 Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed) Apply for PAR 25 165 Funding Number: PAR 25 165 Agency: National Institutes of Health Funding Amount: Case Dependent Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Optional) Apply for PAR 25 209 Funding Number: PAR 25 209 Agency: National Institutes of Health Funding Amount: Case Dependent Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed) Apply for PAR 25 273 Funding Number: PAR 25 273 Agency: National Institutes of Health Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional) Apply for PA 25 246 Funding Number: PA 25 246 Agency: National Institutes of Health Enhancing Reuse of NHGRI Data Assets (R03 Clinical Trial Not Allowed) Apply for RFA HG 25 005 Funding Number: RFA HG 25 005 Agency: National Institutes of Health Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional) Apply for PAR 25 039 Funding Number: PAR 25 039 Agency: National Institutes of Health Funding Amount: Case Dependent Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed) Apply for PAR 25 037 Funding Number: PAR 25 037 Agency: National Institutes of Health Funding Amount: Case Dependent Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional) Apply for PAR 25 040 Funding Number: PAR 25 040 Agency: National Institutes of Health Funding Amount: Case Dependent Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed) Apply for PAR 25 038 Funding Number: PAR 25 038 Agency: National Institutes of Health Funding Amount: Case Dependent Limited Competition: Small Grant Program for ORIP Special Emphasis Research Career Award (SERCA) K01 Recipients (R03 Clinical Trial Not Allowed) Apply for PAR 25 176 Funding Number: PAR 25 176 Agency: National Institutes of Health Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional) Apply for PAR 25 067 Funding Number: PAR 25 067 Agency: National Institutes of Health Funding Amount: Case Dependent Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional) Apply for PAR 25 065 Funding Number: PAR 25 065 Agency: National Institutes of Health Funding Amount: Case Dependent Social disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional) Apply for PAR 25 066 Funding Number: PAR 25 066 Agency: National Institutes of Health Funding Amount: Case Dependent NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed) Apply for PAR 25 105 Funding Number: PAR 25 105 Agency: National Institutes of Health Funding Amount: Case Dependent Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional) Apply for PAR 25 064 Funding Number: PAR 25 064 Agency: National Institutes of Health Funding Amount: Case Dependent NIDCR Research Grants for Analyses of Existing Genomics Data (R01) (Clinical Trial Not Allowed) Apply for PAR 25 164 Funding Number: PAR 25 164 Agency: National Institutes of Health Funding Amount: Case Dependent Aging Research Dissertation Awards to Promote Diversity (R36 Clinical Trial Not Allowed) Apply for PAR 24 130 Funding Number: PAR 24 130 Agency: National Institutes of Health Funding Amount: Case Dependent Grant application guides and resources It is always free to apply for government grants.

However the process may be very complex depending on the funding opportunity you are applying for. Let us help you! Inside Our Applicants Portal Applicant Video Guides - The grant application process can be challenging to follow.

We can help you with intuitive video guides to speed up the process and eliminate errors in submissions. Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.

Premium leads for funding administrators, grant writers, and loan issuers Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience. Request more information: Would you like to learn more about this funding opportunity, similar opportunities to " RFA NS 25 025 ", eligibility, application service, and/or application tips? Submit an inquiry below: Request for More Information